Risperidone and ethyl pyruvate have protective effects against ketamine-induced cognitive impairments in mice


Kelle I., Eriman H., Erdinc M., Uyar E.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.26, no.5, pp.1708-1716, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 5
  • Publication Date: 2022
  • Journal Name: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.1708-1716
  • Keywords: Ethyl pyruvate, Risperidone, Ketamine, Schizophrenia, Cognitive symptoms, NMDA RECEPTOR ANTAGONISTS, NEURONAL CELL-DEATH, OXIDATIVE STRESS, RECOGNITION MEMORY, MODEL, SEROTONIN, DAMAGE, BRAIN, DOPAMINE-D-2, PERFORMANCE
  • Inonu University Affiliated: Yes

Abstract

OBJECTIVE: Ketamine, an N-methyl D-aspartic acid receptor antagonist drug, is reported to produce memory disruptions. The aim of this study was to investigate the protective effects of ethyl pyruvate (EP), a pyruvic acid derivative, and risperidone, an atypical anti-psychotic drug, against ketamine-induced cognitive disturbances.